Partnering Opportunities

For industry and societal partners, Luris serves as the gateway to Leiden’s very best. By working as the vital link between the academic and the partner and by capitalizing on our experience with these interactions and transactions, we increase your chances of success.

Patents and licenses of novel technology ready to be transferred are offered as partnering opportunities. Luris manages these and targets potential parties who will enable the technology or research to have the biggest possible impact on society. Have a look at the partnering opportunities right now.

Looking for a specific solution? Is there a question you can’t find the answer to? Or are you looking for a specialist who can take your innovation further? Please discuss it with one of our Business Developers.

Interested in all the technologies that all universities and medical centers in the Netherlands have to offer? Visit the knowledge and tech partnering opportunities website.

Service offered: Transmission electron microscopy imaging

Market sectors: Research and Development

Service offered: scanning electron microscopy imaging

Market sectors: Research, Drug Discovery and Development

Service offered: Lipid nanoparticle analysis using cryo electron microscopy imaging

Market sectors: Research, Drug Discovery and Development

Service offered: Extracellular Vesicle analysis using cryo electron microscopy imaging

Market sectors: Research, Drug Discovery and Development

LAHR: IMPROVED GENOME EDITING ACCURACY AND EFFICIENCY

The present invention, termed Ligation-Assisted Homologous Recombination (LAHR), represents an innovative genome editing strategy that combines the genome editing capabilities of CRISPR/Cas12a technology with the high-fidelity of a dual repair mechanism.

ANTISENSE OLIGONUCLEOTIDE THERAPY FOR HUNTINGTON’S DISEASE

Leiden University Medical Center's NeuroD research group has developed an antisense oligonucleotide (ASO) therapy for Huntington's Disease (HD), targeting the disease-causing HTT transcript.

ANTISENSE OLIGONUCLEOTIDE THERAPY FOR D-CAA AND ALZHEIMER'S DISEASE

Leiden University Medical Center's NeuroD research group has developed an innovative antisense oligonucleotide (ASO) therapy targeting APP gene mutations, applicable to D-CAA and Alzheimer's Disease (AD). This therapy is designed to modulate APP pre-mRNA splicing, reducing harmful amyloid-beta production.

Service Offered: High-Throughput Profiling of Protein N-Glycosylation Employing Linkage-Specific Sialic Acid Esterfication

The team of Professor Manfred Wuhrer at Leiden University Medical Center (LUMC), have developed a rapid, robust and linkage-specific high-throughput method for sialic acid stabilization and analysis of complex glycoprotein mixtures such as human plasma N-glycome.

Service Offered: Cell Model of Immune Responses

Scientists at Leiden University Medical Center (LUMC), have developed a dendritic cell culture system as a read-out of the immune response and as a replacement for animal testing.

Cytotoxicity of Synthesized EPD (EPD-S), A Natural Sesquiterpene Lacton, and its Future Clinical Efficacy

The present invention is relating to a new anti-cancer drug, EPD-S. This drug shows on itself, as well as in combination with paclitaxel and cisplatin, strong cytotoxicity against ovarian cancer and other cancer types.

Targeted Complement Inhibition

We have developed strategies to target complement inhibition to specific tissues / cells to achieve local complement inhibition while leaving the systemic complement pool available to fight infections and achieve homeostasis.

Targeting ligand-bound (solid-phase) C1q

We have recently developed recombinant fully human antibodies that strongly bind to C1q that is bound to its ligands (solid-phase) but does not bind to circulating C1q.